Simple Summary Acute myeloid leukemia (AML) is an aggressive blood cancer disease that
can only be cured by intensive anticancer treatment, and for several patients, allogeneic …

Myeloid leukemia denotes a hematologic malignancy characterized by aberrant proliferation
and impaired differentiation of blood progenitor cells within the bone marrow. Despite the …

Background Patients with relapsed or refractory acute myeloid leukemia (R/R AML) and
FLT3‐internal tandem duplication (FLT3‐ITD) respond infrequently to salvage …

Background Limited data were available to understand the significance of ferroptosis in
leukemia prognosis, regardless of the genomic background. Methods RNA-seq data from …

(1) Background: Relapsed/refractory (r/r) and secondary acute myeloid leukemia are
highlighted by chemoresistance and poor outcomes. The aim of the study was to assess the …

This study reports characteristics and outcomes of adults who received Azacitidine-
Venetoclax (AZA-VEN) compared to other salvage therapies (NO-AZA-VEN) as first salvage …

Background: Adult patients with Acute Myeloid Leukemia (AML) have traditionally been
hospitalized for the duration of intensive consolidation chemotherapy until blood count …

Anti-CD22 Calicheamicin-Inotuzumab Ozogamicin Combined with Venetoclax + Azacitidine in
the Treatment of Mixed-Phenotype Acute Leukemia: A Case Report - PMC Skip to main content …

Acute myeloid leukemia (AML) is a malignant bone marrow disorder arising from early
myeloid progenitors leading to clonal expansion and myeloid maturation arrest [1]. It is the …

A 57-year-old patient was diagnosed with MLAL by presenting hyperleukocytosis and
anemia. Bone marrow morphology test presents 86% lymphoid blasts. Flow cytometry …